CTLT:NYE-Catalent Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 58.48

Change

-0.21 (-0.36)%

Market Cap

USD 10.78B

Volume

1.71M

Analyst Target

USD 102.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
HLN Haleon plc

+0.01 (+0.10%)

USD 43.99B
ELAN Elanco Animal Health

+0.11 (+0.88%)

USD 6.18B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M
EBS Emergent Biosolutions Inc

+0.19 (+2.17%)

N/A

ETFs Containing CTLT

UTRN Vesper U.S. Large Cap Sho.. 4.03 % 0.00 %

+0.31 (+0.35%)

USD 0.02B
EVNT AltShares Event-Driven ET.. 3.94 % 0.00 %

+0.03 (+0.35%)

USD 4.87M
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.02 (+0.35%)

USD 2.57B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.41 (+0.35%)

N/A
JKK 0.00 % 0.30 %

N/A

N/A
MNA IQ Merger Arbitrage ETF 0.00 % 0.76 %

+0.07 (+0.35%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.19 (+0.35%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
USLB 0.00 % 0.35 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

+0.36 (+0.35%)

USD 5.05B
TWOK 0.00 % 0.10 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.36 (+0.35%)

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

+0.09 (+0.35%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.16% 73% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.16% 73% C 85% B
Trailing 12 Months  
Capital Gain 67.95% 73% C 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.95% 73% C 89% A-
Trailing 5 Years  
Capital Gain 18.74% 79% B- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.74% 79% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.75% 53% F 59% D-
Dividend Return 6.75% 47% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.20% 40% F 18% F
Risk Adjusted Return 13.45% 53% F 32% F
Market Capitalization 10.78B 60% D- 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector